Jabbour Jerome D 4
4 · Matinas BioPharma Holdings, Inc. · Filed Jun 24, 2021
Insider Transaction Report
Form 4
Jabbour Jerome D
DirectorPresident and CEO
Transactions
- Conversion
Series B Preferred Stock
2021-06-19−15→ 0 totalExercise: $0.50From: 2018-06-21→ Common Stock (30,000 underlying) - Conversion
Common Stock, par value $0.0001 per share
2021-06-19+30,000→ 840,011 total - Other
Common Stock, par value $0.0001 per share
2021-06-19+6,000→ 810,011 total
Footnotes (2)
- [F1]Stock dividend, payable to all holders of record of Series B Preferred Stock of 400 shares of Common Stock for each share of Series B Preferred Stock.
- [F2]On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the "Certificate") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date.